RICHMOND, VA., October 23 /CNW/ - Insmed Inc. (Nasdaq: INSM), a
biopharmaceutical company focused on the development and approval of drugs for
the treatment of metabolic diseases with unmet medical needs, today announced
that it will present at the Acumen BioFin Rodman & Renshaw 9th Annual
Healthcare Conference in New York City.
The conference, to be held at the New York Palace Hotel, will run from
Monday, November 5th through Wednesday, November 7th. Geoffrey Allan, Ph.D.,
Insmed's President and CEO, will make the presentation on Tuesday, November 6,
2007 at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time).
"We look forward to participating at this important healthcare investor
conference where we will provide an update on the progress of our
dual-strategy growth plan based on our proprietary protein platform and the
development and manufacture of follow-on biologics," said Dr. Allan.
The Company will also hold one-on-one meetings with investment firm
Individuals interested in listening to the live presentation via the
Internet may do so by visiting www.insmed.com. A replay will be available on
the Company's Web site for 30 days.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the development of drug
candidates for the treatment of metabolic diseases and endocrine disorders
with unmet medical needs. For more information, please visit www.insmed.com.
Forward Looking Statements
This release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of 1934. Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for existing or
proposed products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ materially from
those anticipated by the forward-looking statements. The risks and
uncertainties include, without limitation, risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured, the
Company may lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies differently than the
Company, competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical industry may
experience negative market trends and other risks and challenges detailed in
the Company's filings with the U.S. Securities and Exchange Commission,
including the Company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2007. Readers are cautioned not to place undue reliance on any
forward-looking statements which speak only as of the date of this release.
The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
For further information:
For further information: Investor Relations International Haris Tajyar,